This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Logo

Clinical Outcomes Of Mega-dosage Supplementations Of Cholecalciferol In Critically Ill Patients With Sepsis

Sponsored by Chimei Medical Center

About this trial

Last updated 2 years ago

Study ID

CMMC11302007

Status

Not yet recruiting

Type

Interventional

Phase

N/A

Placebo

Yes

Accepting

18 to 100 Years
All Sexes

Trial Timing

Started 2 years ago

What is this trial about?

Non-COVID-19 sepsis (Sepsis) has always been one of the common diseases in critically ill patients. The main treatment strategy is to kill pathogens and mitigate hyperinflammation. One study demonstrated that the supplementation with 576,000 IU cholecalciferol (vitamin D3) as a single dose in critically ill adults in the medical intensive care units (MICUs) can improve clinical outcomes, including acute physiology and chronic health evaluation II score (APACHE II), sequential organ failure assessment score (SOFA), and C-reactive protein (CRP). It is a three-year, multi-center, prospective, parallel, double-blind, randomized controlled clinical trial for 240 eligible subjects, with administrations of vitamin D3 576,000 IU or placebo every 24 hours for 3 days (72 hours) within 96 hours after intensive care unit (ICU) admission.

What are the participation requirements?

Inclusion Criteria

1. Medical subject ≥ 18 years old and diagnosed with sepsis

2. Transferred to the intensive care unit within 24 hours after being diagnosed with sepsis

3. Admitted to the ICU with 40 > APACHE II score ≥ 15.

4. The intensivist anticipates that the subject will stay in the ICU ≥ 7 days.

Exclusion Criteria

1. Diseases that affect serum levels of 25(OH)D and calcium, including thyroidectomy, parathyroid disease, rickets, or severe cirrhosis [Child C]

2. Received large doses of vitamin D3 in the past four weeks (> 2000 IU per day or ≥ 10,000 IU in a single dose)

3. Admitted to the ICU with diagnosis of COVID-19

4. AIDS subjects taking immunosuppressants

5. Organ transplant

6. Active cancer

7. Tuberculosis, sarcoidosis, or kidney stones in the past one year

8. Weight < 45 kg or > 90 kg

9. Had been admitted to ICU in the past three months

10. Subject and family members who do not speak the native language

11. Pregnant women